Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo aims to wipe out stubborn leukemia cells

NCT ID NCT06660368

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 23 times

Summary

This study tests whether adding venetoclax to standard chemotherapy (CLAG-M) helps people with relapsed or treatment-resistant acute myeloid leukemia (AML) achieve deeper remission. About 52 adults aged 18-80 will be randomly assigned to receive either the combo or chemo alone. The goal is to improve event-free survival and reduce cancer cells to undetectable levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana-Farber Cancer Institute

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.

RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)